You can buy or sell AKBA and other stocks, options, ETFs, and crypto commission-free!
Akebia Therapeutics, Inc. Common Stock, also called Akebia Therapeutics, is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. Read More It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. It offers vadadustat, which is an oral therapy for the treatment of anemia due to chronic kidney disease. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
The Motley FoolMar 19
Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript
Akebia Therapeutics (NASDAQ:AKBA) Q4 2018 Earnings Conference Call March 18, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Akebia Therapeutics preliminary full-year 2018 financial results and business highlights conference call. As a reminder, this conference call is being recorded. [Operator instructions] I would now like to introduce your host for today's conference. Megan, the flo...
Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease, today announced preliminary financial results for the full year ended December 31, 2018 and business highlights. “2018 was a transformational year for Akebia,” said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. “We successfully executed a number of strategic initiatives to a...
The Motley FoolMar 12
Why Akebia Therapeutics, Momo, and Switch Jumped Today
The stock market generally kept gaining ground on Tuesday, with only downward pressure from the most heavily weighted component of the Dow Jones Industrial Average preventing a clean sweep of every major benchmark posting solid gains.
-$0.24 per share
Available Mar 18, After Hours